GlassScriptPhysician profile
Alan J Parks
NPI 1598751653
$4,894.00
in general payments reported to CMS, 2019-2025
27 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $304 · 2022: $340 · 2023: $557 · 2024: $864 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.35 |
| Education | $322.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,509.13 | 2019-2025 | |
| Janssen Biotech, INC. | $714.32 | 2019-2025 | Tremfya |
| Pfizer INC. | $573.04 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $347.60 | 2019 | |
| Leo Pharma INC. | $305.92 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $201.50 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $146.20 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Celgene Corporation | $135.63 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.78 | 2019-2020 | |
| Amgen INC. | $103.93 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $100.28 | 2019-2020 | |
| Ucb, INC. | $87.25 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $73.55 | 2019-2020 | |
| Dermavant Sciences, INC. | $67.45 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $62.68 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.25 | 2019 | |
| Journey Medical Corporation | $59.70 | 2019 | |
| Mayne Pharma Commercial LLC | $44.47 | 2019 | |
| Almirall LLC | $39.65 | 2025 | Seysara |
| Dermira, INC. | $39.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Aclaris Therapeutics, INC. | $17.18 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.90 | 2019 | |
| Encore Dermatology INC. | $15.81 | 2020 | |
| Genentech USA, INC. | $15.81 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $14.97 | 2019 | |
| Strata Skin Sciences, INC. | $13.78 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.